Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Seville
Clinical trial register · Spain

Clinical Trials in Seville, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Spain and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5875 matching records held by the registry are in this view. Synced 11 Oct 2026, 03:18 UTC
5875
Studies in scope
all four open statuses
3096
Recruiting now
open to new participants
1137
Lead sponsors
across recruiting studies
Top sites
Barcelona 3238 Madrid 3046 Valencia 1215 Seville 1054 Málaga 746
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca71 Hoffmann-La Roche48 Merck Sharp & Dohme LLC47 Janssen Research & Development, LLC40 Eli Lilly and Company37
Site location
Barcelona3238 Madrid3046 Valencia1215 Seville1054 Málaga746
All 453 locations
Target enrolment
to

Trials with a site in Seville

1054 of 5875 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Spain
Start
Active, closed
Eli Lilly and Company
Phase 3
533
Barcelona, Seville, Valencia, Valladolid
2018-03-14
Active, closed
AstraZeneca
Phase 2
273
Barcelona, Cáceres, Madrid, Palma de Mallorca, San Sebastián, Sant Cugat del Vallès, Seville, Valencia
2018-03-07
Recruiting
Mucopolysaccharidosis VII Disease Monitoring Program
NCT03604835Mucopolysaccharidosis VII, MPS VII, MPS 7, Sly Syndrome
Ultragenyx Pharmaceutical Inc
Observational
50
Seville
2018-01-29
Recruiting
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
NCT03394365Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant
DrugTabelecleucel
Pierre Fabre Medicament
Phase 3
115
Badalona, Barcelona, Santander, Madrid, Seville, Valencia
2017-12-29
Recruiting
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
NCT03328078Relapsed Hematologic Malignancy, Refractory Hematologic Malignancy, Relapsed Primary Central Nervous System Lymphoma, Refractory Primary Central Nervous System Lymphoma
DrugsEmavusertib·Ibrutinib
Curis, Inc.
Phase 1/2
152
Barcelona, Madrid, Seville
2017-12-28
Active, closed
AstraZeneca
Phase 2
528
Barcelona, Madrid, Seville
2017-12-18
Active, closed
ViiV Healthcare
Phase 3
1,049
Badalona, Barcelona, Córdoba, Elche Alicante, Madrid, Málaga, Santiago de Compostela, Seville
2017-10-27
Recruiting
Italfarmaco
Phase 2/3
206
Esplugues de Llobregat, Barcelona, Seville, Valencia
2017-10-24
Active, closed
Hoffmann-La Roche
Phase 2/3
1,000
L'Hospitalet de Llobregat, Santiago de Compostela, Pamplona, Alicante, Barcelona, Madrid, Málaga, Seville
2017-09-22
Active, closed
Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers
NCT03212404Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Small Cell, Malignant Mesothelioma, Advanced
Checkpoint Therapeutics, Inc.
Phase 1
272
Barcelona, Madrid, Málaga, Pamplona, San Cristóbal de La Laguna, Seville, Valencia
2017-09-20
Active, closed
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)
NCT03767348Non-Small Cell Lung Cancer (NSCLC), Microsatellite Instability-High (MSI-H), Non-melanoma Skin Cancer (NMSC), Cutaneous Melanoma
DrugsVusolimogene Oderparepvec·Opdivo·Nivolumab
Replimune, Inc.
Phase 2
340
Barcelona, Madrid, Murcia, Pamplona, Seville, Valencia
2017-09-20
Active, closed
Novartis Pharmaceuticals
Phase 3
206
Donostia / San Sebastian, Barcelona, Madrid, Seville, Valencia
2017-08-23
Active, closed
Breast Cancer Trials, Australia and New Zealand
Not applicable
1,167
Barcelona, Lleida, Seville
2017-08-21
Active, closed
Asthma Research in Children and Adolescents
NCT04480242Persistent Asthma, Asthma in Children, Asthma Exacerbation
Parc de Salut Mar
Observational
525
Cadiz, Seville, Zaragoza, Alava, Torrelavega, Barcelona, Madrid, Valencia
2017-07-26
Active, closed
Hoffmann-La Roche
Phase 2
316
Sant Cugat del Vallès, Donostia / San Sebastian, Alcorcón, Pamplona/iruña, Barcelona, Madrid, Seville
2017-06-27
Active, closed
Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation
NCT03173248Newly Diagnosed Acute Myeloid Leukemia (AML), Untreated AML, AML Arising From Myelodysplastic Syndrome (MDS), Leukemia, Myeloid, Acute
DrugsIvosidenib·Azacitidine
Institut de Recherches Internationales Servier
Phase 3
146
Santiago de Compostela, Palma de Mallorca, Badalona, Las Palmas de Gran Canaria, Barcelona, Madrid, Seville, Valencia
2017-06-26
Active, closed
A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
NCT03165734Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
DrugPacritinib
Swedish Orphan Biovitrum
Phase 3
407
Barcelona, Madrid, Murcia, Salamanca, Seville, Valencia
2017-06-26
Active, closed
Alliance Foundation Trials, LLC.
Phase 3
518
Barcelona, Madrid, Málaga, Murcia, Navarro, Salamanca, Santiago, Seville
2017-06-21
Active, closed
Acerta Pharma BV
Phase 3
635
Badalona, Barcelona, Madrid, Majadahonda, Pamplona, Seville, Valencia
2017-04-05
Active, closed
Bristol-Myers Squibb
Phase 3
1,314
A Coruña, Barcelona, Madrid, Santander, Seville, Valencia
2017-03-24
Recruiting
Italian Sarcoma Group
Not applicable
100
Barcelona, Madrid, Seville, Valencia
2017-03-16
Active, closed
Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor
NCT03069469Advanced Malignant Neoplasm, Pigmented Villonodular Synovitis, Giant Cell Tumor of Tendon Sheath, Tenosynovial Giant Cell Tumor
DrugVimseltinib
Deciphera Pharmaceuticals, LLC
Phase 1/2
120
Barcelona, Madrid, Seville
2017-02-16
Active, closed
Target PharmaSolutions, Inc.
Observational
10,000
Madrid, Pamplona, Santander, Seville, Valencia
2016-12
Recruiting
Neurovascular Product Surveillance Registry
NCT02988128Intracranial Aneurysm, Stroke, Ischemic
Medtronic Neurovascular Clinical Affairs
Observational
4,000
Barakaldo, Barcelona, Madrid, Oviedo, San Sebastián, Seville, Valladolid, Vigo
2016-12
Active, closed
Janssen Research & Development, LLC
Phase 1/2
234
Badalona, Barcelona, Madrid, Málaga, Pamplona, Seville, Valencia
2016-11-21
Active, closed
ViiV Healthcare
Phase 3
618
Badalona, Barcelona, Córdoba, Elche Alicante, Madrid, Málaga, Santiago de Compostela, Seville
2016-10-28
Active, closed
Eisai Inc.
Phase 3
1,069
Santander, Barcelona, Cáceres, Córdoba, Madrid, Oviedo, Seville, Valencia
2016-10-13
Active, closed
Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)
NCT02864992Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification, Lung Adenocarcinoma Stage IIIB/IV
DrugTepotinib
EMD Serono Research & Development Institute, Inc.
Phase 2
337
Barcelona, Cartagena, Jerez de la Frontera, Madrid, Málaga, San Sebastián de los Reyes, Sant Cugat del Vallès, Seville
2016-09-13
Active, closed
Tesaro, Inc.
Phase 3
733
Badalona, Barcelona, Córdoba, Donostia / San Sebastian, Elche Alicante, Girona, Madrid, Seville
2016-07-11
Active, closed
Janssen Research & Development, LLC
Phase 1
751
A Coruña, Barcelona, Madrid, Málaga, Santander, Seville
2016-05-24
Active, closed
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Phase 2
50
Barcelona, Terrassa, Burgos, Alcorcón, Madrid, Cartagena, Marbella, Seville
2016-05-18
Active, closed
MedImmune LLC
Phase 1/2
383
Barcelona, Madrid, Málaga, Pamplona, Seville
2016-02-22
Active, closed
Aragon Pharmaceuticals, Inc.
Phase 1
23
Barcelona, Seville
2016-02-12
Active, closed
Geron Corporation
Phase 2/3
289
Cadiz, Majadahonda, Seville, Valencia, Barakaldo, Badalona, Barcelona, Madrid
2016-01-12
Active, closed
Hoffmann-La Roche
Phase 2
534
Fuenlabrada, Barcelona, Madrid, Málaga, Seville
2015-11-19
Active, closed
AstraZeneca
Phase 3
1,126
Badajoz, Badalona, Barcelona, Elche(Alicante), Madrid, Pozuelo de Alarcón, Santiago de Compostela, Seville
2015-11-02
Recruiting
CAR-T Long Term Follow Up (LTFU) Study
NCT02445222Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program
Novartis Pharmaceuticals
Phase 3
1,105
Esplugues, L'Hospitalet de Llobregat, Pamplona, Barcelona, Madrid, Salamanca, Seville, Valencia
2015-11-02
Recruiting
Centre Leon Berard
Phase 2/3
536
Seville
2015-06-02
Active, closed
Eli Lilly and Company
Phase 3
545
Barcelona, Hospitalet, Palma, Pozuelo de Alarcón, Madrid, Pamplona, Seville, Valencia
2015-05-06
Recruiting
The European NAFLD Registry
NCT04442334NAFLD, NASH, NASH - Nonalcoholic Steatohepatitis, Fibrosis, Liver
Newcastle University
Observational
10,000
Barcelona, Donostia / San Sebastian, Majadahonda, Santander, Seville, Valladolid
2015-05-01
Active, closed
ViiV Healthcare
Phase 3
371
Badalona, Barcelona, Madrid, Seville
2015-02-23
Active, closed
Karyopharm Therapeutics Inc
Phase 2
244
Badalona, Barcelona, Madrid, Palma de Mallorca, Pamplona, Salamanca, Seville
2014-11
Recruiting
Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients
NCT02275286Liposarcoma, Myxoid, Sarcoma, Soft Tissue, Leiomyosarcoma, Liposarcoma
DrugTrabectedin
Grupo Espanol de Investigacion en Sarcomas
Phase 1/2
199
Zaragoza, Barcelona, Palma de Mallorca, San Cristóbal de La Laguna, Madrid, Seville
2014-11
Active, closed
Eli Lilly and Company
Phase 3
453
A Coruña, Barcelona, L'Hospitalet de Llobregat, Madrid, Málaga, Seville, Valencia
2014-10-03
Recruiting
The European Paediatric Network for Haemophilia Management ( PedNet Registry)
NCT02979119Factor VIII Deficiency, Factor IX Deficiency
PedNet Haemophilia Research Foundation
Observational
4,000
Barcelona, Madrid, Seville, Valencia
2014-06
Recruiting
Jules Bordet Institute
Not applicable
1,000
A Coruña, Barcelona, Castellon, Cáceres, Lleida, Madrid, Seville, Valencia
2014-04
Active, closed
Novartis Pharmaceuticals
Phase 1/2
259
Madrid, Seville, Valencia
2013-10-22
Active, closed
AstraZeneca
Phase 3
510
Barcelona, Madrid, Málaga, Seville, Vigo(Pontevedra), Zaragoza
2013-09-25
Active, closed
Novartis Pharmaceuticals
Phase 3
240
Vigo, Barakaldo, Madrid, Málaga, Seville, Valencia
2013-07-26
Active, closed
MedImmune LLC
Phase 2
571
Barcelona, Donostia / San Sebastian, Madrid, Sabadell (Barcelona), Seville
2013-05-17
Recruiting
Atypical Hemolytic-Uremic Syndrome (aHUS) Registry
NCT01522183Atypical Hemolytic-Uremic Syndrome
Alexion Pharmaceuticals, Inc.
Observational
3,000
Barcelona, Pamplona, Seville
2013-03-18
By invitation
Seville Cohort of People Living With HIV at Risk for Anal Cancer
NCT03713229Anal Squamous Intraepithelial Neoplasia
Hospitales Universitarios Virgen del Rocío
Observational
3,000
Seville
2010-09-01
Active, closed
AstraZeneca
Phase 3
736
A Coruña, Madrid, Málaga, Oviedo, Salamanca, Seville
2005-02-13
Recruiting
International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry
NCT00358943Gaucher Disease, Cerebroside Lipidosis Syndrome, Glucocerebrosidase Deficiency Disease, Glucosylceramide Beta-Glucosidase Deficiency Disease
Genzyme, a Sanofi Company
Observational
12,000
A Coruña, Barcelona, Alcorcón, Vigo, Seville, Madrid, Sabadell, Valencia
1991-04-01
Rows per page Showing 1001–1054 of 1054
Previous 1 2 3
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Spanish investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 13 October 2026. https://priyalifescience.com/clinical-trials-spain/city/seville?page=3

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Spain and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,875 studies in total at the last sync on 11 Oct 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 1,054 of those studies with a site in Seville.

How many clinical trials are recruiting in Seville?

491 of the 1,054 studies on this page are recruiting new participants as of the 11 Oct 2026, 03:18 UTC sync. A further 36 have not yet opened recruitment, 508 are active but closed to new participants, and 19 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.